このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

APOE4/4 初期 AD 被験者における ALZ-801 の有効性と安全性の研究 (APOLLOE4)

2026年9月3日 更新者:Alzheon Inc.

初期アルツハイマー病および APOE4/4 遺伝子型の被験者における ALZ-801 の有効性、安全性、およびバイオマーカー効果に関する第 3 相、多施設、無作為化、二重盲検、プラセボ対照試験

This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind, randomized trial with one dose of ALZ-801 compared to placebo.

調査の概要

状態

完了

条件

介入・治療

詳細な説明

This is a multi-center, double-blind study that will evaluate 265 mg twice daily (BID) of ALZ-801, an oral tablet, over 78 weeks as a treatment for subjects (50-80 years old) with Early AD who are homozygous for the ε4 allele of the apolipoprotein gene (APOE4 homozygous or APOE4/4). The primary efficacy outcome assessment is a measure of cognition (ADAS-cog 13). Additional measures of global and functional impairments will also be assessed. Imaging and soluble biomarkers of AD and neurodegeneration will be measured and a sub-study to evaluate cerebrospinal fluid (CSF) biomarkers is also included.

研究の種類

介入

入学 (実際)

325

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Reykjavik、アイスランド、101
        • Memory Clinic, Landspitali University Hospital
    • Arizona
      • Phoenix、Arizona、アメリカ、85004
        • Xenoscience
      • Scottsdale、Arizona、アメリカ、85297
        • CCT Research
      • Sun City、Arizona、アメリカ、85351
        • Banner Sun Health Research Institute
    • California
      • Costa Mesa、California、アメリカ、92626
        • ATP Clinical Research
      • Irvine、California、アメリカ、92780
        • Tilda Research
      • La Jolla、California、アメリカ、92037
        • UCSD Shiley-Marcos Alzheimer's Disease Research Center
      • Lomita、California、アメリカ、90717
        • Torrance Clinical Research Institute
      • Long Beach、California、アメリカ、90806
        • Collaborative NeuroScience Network LLC
      • Palo Alto、California、アメリカ、94304
        • Stanford University
      • Pasadena、California、アメリカ、91105
        • SC3 Research Group
      • Sacramento、California、アメリカ、95816
        • Sutter Health
    • Florida
      • Atlantis、Florida、アメリカ、33462
        • JEM Research Institute, Headlands Site
      • Bradenton、Florida、アメリカ、34205
        • Bradenton Research Center
      • Hialeah、Florida、アメリカ、33016
        • Galiz Research
      • Jupiter、Florida、アメリカ、33458
        • Alphab Global Research
      • Lady Lake、Florida、アメリカ、32159
        • Charter Research
      • Maitland、Florida、アメリカ、32751
        • K2 Medical Research, LLC
      • Miami、Florida、アメリカ、33137
        • Miami Jewish Health
      • Miami、Florida、アメリカ、33144
        • Y & L Advance Health Care, Inc /DBA Elite Clinical Research
      • Miami Beach、Florida、アメリカ、33140
        • Mount Sinai Medical Center
      • Naples、Florida、アメリカ、34105
        • Aqualane Clinical Research
      • Orlando、Florida、アメリカ、32819
        • Headlands Research Orlando
      • Orlando、Florida、アメリカ、32803
        • Charter Research
      • Palm Beach Gardens、Florida、アメリカ、33410
        • Advanced Research Consultants
      • Pompano Beach、Florida、アメリカ、33064
        • Quantum CNS Clinical Research
      • Port Orange、Florida、アメリカ、32127
        • Progressive Medical Research
      • Stuart、Florida、アメリカ、34997
        • ALZ Research and Treatment Center (A.R.T.C.)
      • Wellington、Florida、アメリカ、33414
        • ALZ Research and Treatment Center (A.R.T.C.)
      • West Palm Beach、Florida、アメリカ、33407
        • Premiere Research Institute
    • Georgia
      • Columbus、Georgia、アメリカ、31909
        • Columbus Memory Center
      • Decatur、Georgia、アメリカ、30030
        • Sandhill Research, LLC
    • Indiana
      • Fort Wayne、Indiana、アメリカ、46804
        • Fort Wayne Neurological Center
    • Louisiana
      • Shreveport、Louisiana、アメリカ、71103
        • Louisiana State University Health Sciences Center (LSUHSC)
    • Massachusetts
      • Plymouth、Massachusetts、アメリカ、02360
        • Headlands Research Eastern MA
    • Nevada
      • Las Vegas、Nevada、アメリカ、89106
        • WR-CRCN
    • New Jersey
      • Toms River、New Jersey、アメリカ、08755
        • Advanced Memory Research Center
    • New York
      • Albany、New York、アメリカ、12208
        • Neurological Associates of Albany
      • New York、New York、アメリカ、10016
        • NYU Alzheimer's Disease Research Center
      • Orangeburg、New York、アメリカ、10962
        • Kline Institute for Psychiatric Research
      • Rochester、New York、アメリカ、14620
        • University of Rochester Medical Center
      • Staten Island、New York、アメリカ、10312
        • Richmond Behavioral Associates
    • North Carolina
      • Greensboro、North Carolina、アメリカ、27410
        • Triad Clinical Trials
      • Matthews、North Carolina、アメリカ、28105
        • AMC Research
    • Ohio
      • Canton、Ohio、アメリカ、44718
        • NeuroScience Research Center
      • Dayton、Ohio、アメリカ、45459
        • Neurology Diagnostics, Inc.
    • Oklahoma
      • Oklahoma City、Oklahoma、アメリカ、73106
        • IPS Research
    • Oregon
      • Portland、Oregon、アメリカ、97225
        • Center for Cognitive Health
    • Pennsylvania
      • Abington、Pennsylvania、アメリカ、19001
        • Abington Neurological Associates
      • Allentown、Pennsylvania、アメリカ、18104
        • Lehigh Center for Clinical Research
    • Rhode Island
      • East Providence、Rhode Island、アメリカ、02914
        • Rhode Island Mood & Memory Research Institute
    • Tennessee
      • Nashville、Tennessee、アメリカ、37212
        • Vanderbilt Center for Cognitive Medicine
    • Texas
      • Houston、Texas、アメリカ、77054
        • UT Health Science Center at Houston
    • Virginia
      • Fairfax、Virginia、アメリカ、22031
        • Re:Cognition Health
    • Washington
      • Bellevue、Washington、アメリカ、98007
        • Northwest Clinical Research Center
    • Wisconsin
      • Milwaukee、Wisconsin、アメリカ、53226
        • Medical College of Wisconsin
      • Bristol、イギリス、BS32 4SY
        • Re:Cognition Health Ltd Bristol
      • London、イギリス、EC2Y 8EA
        • St. Pancras Clinical Research
      • Winchester、イギリス、SO21 1HU
        • Re-Cognition Health Ltd Winchester
    • Devon
      • Plymouth、Devon、イギリス、PL6 8BT
        • Re-Cognition Health Ltd Plymouth
    • Greater London
      • London、Greater London、イギリス、W1G 9JF
        • Re-Cognition Health Ltd London
    • North Lanarkshire
      • Motherwell、North Lanarkshire、イギリス、ML1 4UF
        • NeuroClin Glasgow Ltd
    • Surrey
      • Guildford、Surrey、イギリス、GU2 7YD
        • Re-Cognition Health Ltd Guildford
    • West Midlands
      • Birmingham、West Midlands、イギリス、B16 8LT
        • Re-Cognition Health Ltd Birmingham
      • 's-Hertogenbosch、オランダ、5223 LA
        • Brain Research Center Den Bosch
      • Amsterdam、オランダ、1081 GN
        • Brain Research Center Amsterdam
      • Zwolle、オランダ、8025 AZ
        • Brain Research Center Zwolle
    • British Columbia
      • Kelowna、British Columbia、カナダ、V1Y 1Z9
        • OCT Research ULC (dba Okanagan Clinical Trials)
    • Nova Scotia
      • Halifax、Nova Scotia、カナダ、B3S 1N2
        • Centricity Research
      • New Minas、Nova Scotia、カナダ、B4N 3R7
        • Centricity Research
    • Ontario
      • Ottawa、Ontario、カナダ、K1Z 1G3
        • Recherches Neuro-Hippocampe Inc., d/b/a Ottawa Memory Clinic
      • Peterborough、Ontario、カナダ、K9H 2P4
        • Kawartha Centre - Redefining Healthy Aging
      • Toronto、Ontario、カナダ、M3B 2S7
        • Toronto Memory Program
    • Quebec
      • Gatineau、Quebec、カナダ、J8T 8J1
        • Recherches Neuro-Hippocampe Inc. d/b/a Clinique de la Mémoire de l'Outaouais
      • Barcelona、スペイン、08028
        • Fundacia ACE - Institut Catala de Neurociencies Aplicadas
      • Madrid、スペイン、28040
        • Hospital Clinico San Carlos
      • Madrid、スペイン、28027
        • Clinica Universidad de Navarra
      • Pamplona、スペイン、31008
        • Clinica Universidad de Navarra
      • Terrassa、スペイン、08221
        • Hospital Universitari MutuaTerrassa
      • Valencia、スペイン、46017
        • Centro Hospital Universitario Dr. Preset
      • Brno、チェコ、656 91
        • Fakultní nemocnice u sv. Anny v Brně (St. Anne's University Hospital)
      • Brno、チェコ、602 00
        • Medica 111, Spol. s r.o. - Neurologicka a Rehabilitacni Ambulance Brno, Centralni Pracoviste v Brne
      • Prague、チェコ、160 00
        • Neuropsychiatrie s.r.o.
      • Rychnov nad Kněžnou、チェコ、51601
        • Vestra Clinics - Dedicated Research Clinics
      • Aachen、ドイツ、52074
        • University Hospital RWTH Aachen Neurological Study Center
      • München、ドイツ、80336
        • Klinikum der Universitaet Muenchen Innenstadt
      • Tübingen、ドイツ、72076
        • Universitätsklinik fuer Psychiatrie und Psychotherapie
      • Westerstede、ドイツ、26655
        • Studienzentrum Nord-West
      • Marseille、フランス、13385
        • Centre Hospitalier Universitaire de Marseille - Hôpital de la Timone
      • Montpellier、フランス、43431
        • Hopital Gui de Chauliac - CHRU de Montpellier
      • Paris、フランス、75475
        • Hopital Lariboisiere - Fernand-Widal - AP-HP
      • Rouen、フランス、76031
        • Centre Hospitalier Universitaire (CHU) Hopitaux de Rouen
      • Strasbourg、フランス、67200
        • Hopitaux Universitaires de Strasbourg Centre d'Investigation Clinique
      • Toulouse、フランス、31059
        • Centre de Recherche Clinique du Gerontopole - CHU Toulouse
      • Villeurbanne、フランス、69100
        • Centre de Recherche-Hopital Geriatrique de Charpennes

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

50年~80年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Clinical diagnosis of MCI or Mild Dementia due to AD consistent with the National Institute on Aging-Alzheimer's Association (NIA-AA) Working Group Criteria.
  • Homozygous for the ε4 allele of the apolipoprotein E gene (APOE4/4).
  • MMSE score at Screening of 22 to 30 (inclusive).
  • CDR - Global score of 0.5 or 1 and CDR Memory Box Score of ≥ 0.5.
  • RBANS delayed memory index score ≤ 85.
  • Evidence of progressive memory loss over the last 12 months per investigator assessment

Exclusion Criteria:

  • Brain magnetic resonance imaging (MRI) indicative of significant abnormality per central reader, other than AD related atrophy. Computed tomography (CT) scan acceptable for subjects who cannot undergo MRI.
  • Diagnosis of neurodegenerative disorder other than AD.
  • Diagnosis of major depressive disorder (MDD) within one year prior to screening.
  • Currently taking memantine or has taken memantine within 12 weeks prior to the Baseline Visit.
  • History of suicidal behavior within one year prior to screening or has ongoing suicidal ideation.
  • History of seizures, excluding febrile seizures of childhood or a single distant seizure (> 5 years).
  • Medically confirmed history of recent cerebral infarct or transient ischemic attack within one year prior to screening.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
実験的:ALZ-801

ALZ-801 265 mg BID tablet orally. Subjects will receive placebo in the morning and one tablet of ALZ-801 265 mg tablet in the evening during the first two weeks of the study; thereafter, they will receive a 265 mg tablet twice daily (BID).

ALZ-801 tablet 265 mg once daily in the evening for the first 2 weeks, then ALZ-801 tablet 265 mg BID

他の名前:
  • バリルトラミプロセート
  • トロミプロシートプロドラッグ

Placebo tablet BID

プラセボコンパレーター:Placebo

Subjects in the placebo treatment arm will receive placebo tablets BID throughout the study

Placebo tablet BID

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Primary Cognitive Efficacy Endpoint (ADAS-Cog13)
時間枠:Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog13) scores.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
Incidence, Nature, and Severity of Treatment Emergent Adverse Events (TEAE)
時間枠:Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

Safety and tolerability as measured by incidence, nature and severity of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs leading to withdrawal.

Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

二次結果の測定

結果測定
メジャーの説明
時間枠
Key Secondary Endpoint (A-IADL-W)
時間枠:Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
Key Secondary Endpoint (CDR-SB)
時間枠:Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
Functional Assessment (DAD)
時間枠:Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Global Cognition Assessment (MMSE)
時間枠:Baseline to Week 78

Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills.

Baseline to Week 78

その他の成果指標

結果測定
メジャーの説明
時間枠
Imaging Biomarker Endpoint (Hippocampal Volume)
時間枠:Baseline to Week 78

Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration.

Baseline to Week 78
Imaging Biomarker Endpoint (Cortical Thickness [Whole Cortex])
時間枠:Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration.

Baseline to Week 78
Imaging Biomarker Endpoint (Cortical Thickness [Mayo Index])
時間枠:Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe.

Baseline to Week 78
Imaging Biomarker Endpoint (Whole Brain Volume)
時間枠:Baseline to Week 78

Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Imaging Biomarker Endpoint (Ventricular Volume)
時間枠:Baseline to Week 78

Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Imaging Biomarker Endpoint - DTI in Grey Matter Mean Diffusivity - Bilateral Caudate
時間枠:Baseline to Week 78

Change from baseline in Grey Matter Mean Diffusivity (Bilateral Caudate) as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). The mean diffusivity (MD) is the average of the three main diffusion values (eigenvalues) obtained from the diffusion tensor imaging (DTI). It is expressed as mm2/s. This unit quantifies the average rate of water diffusion across all directions within a tissue, providing an overall measure of tissue microstructural properties. Lower MD value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as lower mean diffusivity compared with the placebo group.

Baseline to Week 78
Imaging Biomarker Endpoint - DTI in White Matter Mean Diffusivity (Bilateral Fornix)
時間枠:Baseline to Week 78

Change from baseline in Bilateral Fornix White Matter Mean Diffusivity as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). The mean diffusivity (MD) is the average of the three main diffusion values (eigenvalues) obtained from the diffusion tensor imaging (DTI). It is expressed as mm2/s. This unit quantifies the average rate of water diffusion across all directions within a tissue, providing an overall measure of tissue microstructural properties. Lower MD value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as lower mean diffusivity compared with the placebo group.

Baseline to Week 78
Imaging Biomarker Endpoint - White Matter Fractional Anisotropy (Bilateral Fornix)
時間枠:Baseline to Week 78

Change from baseline in Bilateral Fornix White Matter Fractional Anisotropy as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). Fractional anisotropy (FA) is a unitless, scalar value that measures the degree of anisotropic (directional) water diffusion within a voxel, ranging from 0 to 1. A value of 0 indicates perfectly isotropic (equal in all directions) diffusion, while a value of 1 indicates perfectly anisotropic (directional) diffusion. Higher FA value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as higher FA in the ALZ-801 group compared with the placebo group.

Baseline to Week 78
Cognitive Efficacy Endpoint (ADAS-Cog 13) - MCI Subgroup
時間枠:Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Mild Alzheimer's Disease(Mild AD) Subgroup
時間枠:Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
A-IADL-W - MCI Subgroup
時間枠:Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
A-IADL-W - Mild AD Subgroup
時間枠:Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
CDR-SB - MCI Subgroup
時間枠:Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
CDR-SB - Mild AD Subgroup
時間枠:Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
Functional Assessment (DAD) - MCI Subgroup
時間枠:Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Functional Assessment (DAD) - Mild AD Subgroup
時間枠:Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Global Cognition Assessment (MMSE) - MCI Subgroup
時間枠:Baseline to Week 78

Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills.

Baseline to Week 78
Global Cognition Assessment (MMSE) - Mild AD Subgroup
時間枠:Baseline to Week 78

Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills.

Baseline to Week 78
Hippocampal Volume (MCI Subgroup)
時間枠:Baseline to Week 78

Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration.

Baseline to Week 78
Hippocampal Volume (Mild AD Subgroup)
時間枠:Baseline to Week 78

Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration.

Baseline to Week 78
Cortical Thickness (Whole Cortex) (MCI Subgroup)
時間枠:Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration.

Baseline to Week 78
Cortical Thickness (Whole Cortex) (Mild AD Subgroup)
時間枠:Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration.

Baseline to Week 78
Cortical Thickness (Mayo Index) (MCI Subgroup)
時間枠:Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe versus the whole cortex.

Baseline to Week 78
Cortical Thickness (Mayo Index) (Mild AD Subgroup)
時間枠:Baseline to Week 78

Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe versus the whole cortex.

Baseline to Week 78
Whole Brain Volume (MCI Subgroup)
時間枠:Baseline to Week 78

Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Whole Brain Volume (Mild AD Subgroup)
時間枠:Baseline to Week 78

Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Ventricular Volume (MCI Subgroup)
時間枠:Baseline to Week 78

Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Ventricular Volume (Mild AD Subgroup)
時間枠:Baseline to Week 78

Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI).

Baseline to Week 78
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Female Subgroup of the FAS
時間枠:Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Male Subgroup of the FAS
時間枠:Baseline to Week 78

Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks.

The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity.

Baseline to Week 78
A-IADL-W - Female Subgroup
時間枠:Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
A-IADL-W - Male Subgroup
時間枠:Baseline to Week 78

Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment.

Baseline to Week 78
CDR-SB - Female Subgroup
時間枠:Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
CDR-SB - Male Subgroup
時間枠:Baseline to Week 78

Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity.

Baseline to Week 78
Functional Assessment (DAD) - Female Subgroup
時間枠:Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Functional Assessment (DAD) - Male Subgroup
時間枠:Baseline to Week 78

Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function.

Baseline to Week 78
Treatment Emergent Adverse Events (TEAE) - Females
時間枠:Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

Safety and tolerability as measured by incidence of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs experienced by at least 5% of participants in either treatment group

Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
Treatment Emergent Adverse Events (TEAE) - Males
時間枠:Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

Safety and tolerability as measured by incidence of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs experienced by at least 5% of participants in either treatment group

Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Susan Abushakra, MD、Alzheon Inc.

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年5月19日

一次修了 (実際)

2024年5月29日

研究の完了 (実際)

2024年7月29日

試験登録日

最初に提出

2021年2月22日

QC基準を満たした最初の提出物

2021年2月22日

最初の投稿 (実際)

2021年2月25日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月29日

QC基準を満たした最後の更新が送信されました

2026年9月3日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • ALZ-801-AD301
  • R01AG065253 (米国 NIH グラント/契約)
  • 2020-005755-20 (EudraCT番号)

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。